Loading
Pneumococcal Vaccines / Vaccines, Conjugate / Pneumococcal Infections · Journal article
Human Vaccines & Immunotherapeutics · July 20, 2026
Reinforces what was already believed, rather than introducing something new.
This network meta-analysis indirectly compared PCV20 and PCV15 immunogenicity across shared serotypes using PCV13 as a common comparator. PCV20 elicited comparable or lower opsonophagocytic responses than PCV15 for most shared serotypes, with PCV15 showing significantly higher responses for several serotypes including serotype 3, while PCV20 exceeded PCV15 only for serotype 4.
Network meta-analysis of randomized controlled trials via common comparator. Adults aged 18 years and older enrolled in randomized controlled trials of PCV20 or PCV15.
17 trials met inclusion criteria but only 9 contributed OPA data for 15 serotypes PCV15 showed significantly higher OPA responses than PCV20 for several serotypes, including serotype 3 PCV20 exceeded PCV15 only for serotype 4
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The lack of head-to-head trials and predominantly superior serotype-specific immunogenicity of PCV15, particularly in older adults, suggests vaccine selection should consider serotype-specific immune responses. Direct comparative trials and real-world effectiveness studies are needed to guide clinical decision-making between these higher-valent pneumococcal vaccines.
Network meta-analysis of 17 trials confirms differential serotype-specific immunogenicity between higher-valent pneumococcal vaccines, with PCV15 showing mostly superior responses.
As stated by the source record.
Quoted from the source exactly as published.
The lack of head-to-head trials and predominantly superior serotype-specific immunogenicity of PCV15, particularly in older adults, suggests vaccine selection should consider serotype-specific immune responses. Direct comparative trials and real-world effectiveness studies are needed to guide clinical decision-making between these higher-valent pneumococcal vaccines.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Higher-valent pneumococcal conjugate vaccines (PCV) may reduce adult pneumococcal disease, but no head-to-head trials compare PCV20 vs. PCV15 in adults. We synthesized serotype-specific immunogenicity from randomized controlled trials using a network meta-analysis via the common comparator PCV13. PubMed, Scopus, Cochrane Library, and ClinicalTrials.gov were searched for trials enrolling adults (≥18 y) and evaluating PCV20 or PCV15. The primary endpoint was opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 d, summarized as ratios of means on the log scale. Heterogeneity/inconsistency were assessed and prespecified age-stratified analyses were performed where possible. Seventeen trials met inclusion criteria but nine contributed OPA data for 15 serotypes. Across most shared serotypes, PCV20 elicited comparable or lower OPA responses than PCV15, with significantly higher responses for PCV15 for several serotypes, including 3. PCV20 exceeded PCV15 only for serotype 4. Age-stratified results suggested greater relative advantages for PCV15 in older adults. Direct comparative and real-world effectiveness studies are needed.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.